Parasites, Fungi, and Viruses

1. Front Matter

   Pages i-xiv

   PDF

2. What Are the Problems in Tropical Infections?

   • Anthony Bryceson

   Pages 1-2

3. Epidemic Diseases

   • D. A. Warrell, P. L. Perine, D. W. Krause

   Pages 3-10

4. Progress Achieved in the Chemotherapy of Soil-Transmitted Helminths

   • F. Arfaa, I. Farahmandian

   Pages 11-22

5. The Treatment of Chloroquine-Resistant Falciparum Malaria

   • A. P. Hall

   Pages 23-27

6. The Role of University Research Departments in the Development of Antiparasitic Chemotherapy

   • W. Peters

   Pages 29-34

7. Current Problems in the Chemotherapy of Parasitic Diseases — The Role of the Pharmaceutical Industry

   • O. D. Standen

   Pages 35-42

8. New Nitroimidazoles with a Chemotherapeutic Activity

   • E. Winkelmann, W. Raether

   Pages 43-44

9. New 5-Nitroimidazoles with Antiprotozoal Activity: Effect of Hoe 088 (Pirinidazole)

   • W. Raether, E. Winkelmann

   Pages 45-47

10. Pharmacokinetic and Metabolic Studies with Ornidazole in Man. Comparison with Metronidazole

    • D. E. Schwartz, F. Jeunet

    Pages 49-59

11. The Diagnosis and Treatment of Lambliasis

    • W. Altorfer

    Pages 61-64

12. Treatment of Giardiasis with a Single Oral Dose of Tinidazole

    • Tor Pettersson

    Pages 65-68

13. A Rural Study in Tanzania of the Chemosuppressant Activity of Various Regimes of Co-trimoxazole or Chloroquine in Subjects with P.falciparum Parasitaemia

    • Th. J. Goosen, M. A. L. Goosen, A. J. Salter

    Pages 69-78

14. Results of the Anti-T. Cruzi Activity of Ro 07-1051* IN Man

    • Jose A. Cerisola, Carlos A. Barclay, Humberto Lugones, Oscar Ledesma

    Pages 79-85

15. The Efficiency of Metronidazole ‘Flagyl’* Against Trypanosoma Evansi in vivo

    • A. M. Mandour, A. M. Abd-El Rahman

    Pages 87-90

16. Emericid (31 559 R.P.): a New Anticoccidial

    • F. Benazet, J. R. Cartier, J. Florent, C. Johnson, J. Lunel, D. Mancy

    Pages 91-96

17. Efficiency of Levamisole “Ketrax” on Some Nematode Infections in Assiut Province

    • A. M. Mandour, Laila A. M. Omran

    Pages 97-104

18. Review of Amphotericin B

    • John E. Bennett

    Pages 105-109

19. Polyenes: Actions and Prospects

    • D. Kerridge, N. J. Russell

    Pages 111-116

20. Review of Imidazole Group

    • R. J. Holt

    Pages 117-125

The International Society of Chemotherapy meets every two years to review progress in chemotherapy of infections and of malignant disease. Each meeting gets larger to encompass the extension of chemotherapy into new areas. In some instances, expansion has been rapid, for example in cephalosporins, pen­ icillins and combination chemotherapy of cancer - in others slow, as in the field of parasitology. New problems of resistance and untoward effects arise; reduction of host toxicity without loss of antitumour activity by new substances occupies wide attention. The improved results with cancer chemotherapy, es­ pecially in leukaemias, are leading to a greater prevalence of severe infection in patients so treated, pharmacokinetics of drugs in normal and diseased subjects is receiving increasing attention along with related problems of bioavailability and interactions between drugs. Meanwhile the attack on some of the major bacterial infections, such as gonorrhoea and tubercu­ losis, which were among the first infections to feel the impact of chemotherapy, still continue to be major world problems and are now under attack with new agents and new methods. From this wide field and the 1,000 papers read at the Congress we have produced Proceedings which reflect the variety and vigour of research in this important field of medicine. It was not possible to include all of the papers presented at the Congress but we have attempted to include most aspects of cur­ rent progress in chemotherapy.

• cancer
• chemotherapy
• kinetics
• pharmacokinetics
• research
• resistance
• toxicity

• The Lodon Hospital Medical College, London, UK

  J. D. Williams

• East Birmingham Hospital, Birmingham, UK

  A. M. Geddes

Policies and ethics